0000-0003-3704-1466 Employment
-
Kymera Therapeutics Executive Director2018 - Present
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (32)
- Discovery of Selective and Orally Bioavailable Heterobifunctional Degraders of Cyclin-Dependent Kinase 2 Save
- Developmental toxicology profile of the IRAK4 degrader KT-474 Save
- IRAK4 Is Overexpressed in Hidradenitis Suppurativa Skin and Correlates with Inflammatory Biomarkers Save
- KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors Save
- Discovery of KT-474─a Potent, Selective, and Orally Bioavailable IRAK4 Degrader for the Treatment of Autoimmune Diseases. Save
- Discovery of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates Targeting MYD88 Mutant Diffuse Large B-Cell Lymphoma. Save
- IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial. Save
- P464: PULSE DOSING OF POTENT AND SELECTIVE HETEROBIFUNCTIONAL MDM2 DEGRADER KT-253 DRIVES TUMOR REGRESSION AND DEMONSTRATES DIFFERENTIATED PHARMACOLOGY COMPARED TO P53/MDM2 SMALL MOLECULE INHIBITORS. Save
- Targeted degradation of MERTK and other TAM receptor paralogs by heterobifunctional targeted protein degraders. Save
- A First-in-Class STAT3 Degrader KT-333 in Development for Treatment of Hematologic Cancers Save